Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
NCT ID: NCT05579899
Last Updated: 2025-03-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
119 participants
INTERVENTIONAL
2022-09-27
2023-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
NCT06723405
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
NCT07150845
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
NCT06645821
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
NCT01850849
CorEvitas Atopic Dermatitis Registry: a Study of Post Approval Drug Safety and Effectiveness
NCT04504955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EVO101 Cream
Active Treatment, BID, 8 weeks
EVO101
Topical Cream
Vehicle Cream
Vehicle Treatment, BID, 8 weeks
EVO101
Topical Cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EVO101
Topical Cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Chronic atopic dermatitis for at least 1 year
3. IGA score of 2 or 3
4. BSA of AD involvement of 4-12%
5. EASI of 5-20
Exclusion Criteria
2. Use of biologic therapy within 12 weeks
3. Regular use of tanning booth within 4 weeks
4. Skin condition that could interfere with study assessments
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Evommune, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eugene Bauer, MD
Role: STUDY_DIRECTOR
Evommune, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saguaro Dermatology
Phoenix, Arizona, United States
Clinical Trials Institute of Northwest Arkansas
Fayetteville, Arkansas, United States
Northwest AR Clinical Trials Center, PLLC
Rogers, Arkansas, United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
Metropolis Dermatology
Los Angeles, California, United States
Dermatology Research Associate
Los Angeles, California, United States
Clinical Science Institute
Santa Monica, California, United States
Driven Research, LLC
Coral Gables, Florida, United States
Lenus Research and Medical Group
Miami, Florida, United States
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, United States
The Indiana Clinical Trials Center
Plainfield, Indiana, United States
Minnesota Clinical Study Center
New Brighton, Minnesota, United States
SkinSpecialists, LLC
Omaha, Nebraska, United States
JDR Dermatology Research, LLC
Las Vegas, Nevada, United States
Dermatology Consulting Services, PLLC
High Point, North Carolina, United States
Dermatologists of Southwest Ohio
Mason, Ohio, United States
Oregon Medical Research Center
Portland, Oregon, United States
DermResearch
Austin, Texas, United States
J&S Studies, Inc
College Station, Texas, United States
Center for Clinical Studies, Ltd LLC
Houston, Texas, United States
Pariser Dermatology Specialists
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVO101-AD001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.